“Only through use of mNeonGreen” were Pfizer and BioNTech able to develop and test their vaccine candidate “at light speed,” Allele said in a complaint filed in federal court in San Diego. That allowed the companies to be first to market with a product that earned them “an immediate $400 million in grants and over $4 billion in sales of the vaccine to date,” Allele said. https://www.bloomberg.com/news/articles/2020-10-05/regeneron-antibody-cocktail-used-by-trump-faces-patent-suit
“Only through use of mNeonGreen” were Pfizer and BioNTech able to develop and test their vaccine candidate “at light speed,” Allele said in a complaint filed in federal court in San Diego. That allowed the companies to be first to market with a product that earned them “an immediate $400 million in grants and over $4 billion in sales of the vaccine to date,” Allele said.